Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436618 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
A Phase 2 study of Lymphoma and Leukemia, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
- 3
- Study locations
NCT00436618: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by Mayo Clinic.
NCT00436618 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by Mayo Clinic. The registered enrollment target is 277 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (43% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436618, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or not responded to previous treatment.
Conditions Studied
Interventions
- DRUG Everolimus
Study Locations (3)
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Minnesota
- Mayo Clinic Cancer Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2005-08 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436618
The ClinicalTrials.gov registry entry for NCT00436618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (43% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Everolimus is the first listed.
NCT00436618 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00436618 about?
NCT00436618 is a clinical study titled "Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment". RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying the side effects and how well everolimus works in treating patients with lymphoma that has relapsed or ...
What is the current status of trial NCT00436618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2005-08. Estimated completion is 2019-10-09.
What conditions does trial NCT00436618 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Lymphoproliferative Disorder.
What interventions are being tested in trial NCT00436618?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT00436618?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00436618 being conducted?
This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.